NanoViricides, Inc. is a nano-biopharmaceutical company. The Company is engaged in discovery, development, and commercialization of drugs to combat viral infections using its nanomedicines technology. The Company’s nanoviricide technology enables direct attacks at multiple points on a virus particle. The nanomedicines technology also enables attacking the rapid intracellular reproduction of the virus by incorporating one or more active pharmaceutical ingredients (APIs) within the core of the nanoviricide. The Company is developing antiviral drug candidate, NV-CoV-2 drug for the treatment of COVID-19 infected sick persons. Its other clinical drug candidate NV-HHV-101 a skin cream for the treatment of shingles rash.